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Background: Opioid substitution treatment (OST) has multiple benefits for heroin injectors and is an evidence-based
major component of international treatment. The current qualitative study sought to explore participants’ attitudes to
and reasons for participating in a feasibility randomised trial in primary care offering ‘same day’ OST (methadone) for
injecting heroin users compared to usual care.
Methods: Twenty injecting heroin users (8 intervention and 12 controls; 16 males and 4 females) were interviewed;
purposive sampling was used to select a maximum variation sample from those who agreed; and analysis used
thematic methods.
Results: Motivation to join the trial included the need to secure treatment set against some ambivalence due to
previous negative experiences of trying to obtain OST. Positive effects of securing methadone via the trial, included
self-reported improvements in health and self-care; reduction in crime, stress and drug use. Completing the baseline
questionnaires at recruitment appeared to enhance motivation for treatment for all participants. For some control
participants, this motivation seemed to increase a sense of self-efficacy and cognitive dissonance generated was
resolved by seeking treatment from their GP. Self-determination theory suggests that behaviour change may have
been initiated during the recruitment appointment, resulting in an increased determination to seek treatment amongst
control participants.
Conclusions: Taking part in the ‘script in a day’ trial enabled participants in the intervention arm to gain same-day
access to methadone and reduce their drug use. For those in the control arm, completing the baseline questionnaires
at recruitment appeared to create cognitive dissonance between their current health state and own aspirations, so
increasing motivation for treatment. Over 50% obtained and were still in receipt of OST (methadone or buprenorphine)
at the 3 month follow-up. We suggest that a regular ‘health evaluation’ for injecting heroin users not in treatment,
paired with low-barrier access to treatment, may be a way of exploring this and encouraging more into obtaining OST
more quickly and at the best time for them. This intervention should be delivered without pressure for change.
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Opioid substitution treatment (OST) has a strong evi-
dence base, is a major component of current treatment in
many countries, and has multiple benefits for heroin injec-
tors [1-3]. OST is key to reducing HIV and Hepatitis C
virus prevalence amongst injecting drug users (IDU’s)
[4,5]. Interventions to increase the uptake, or to re-engage
with OST, are routine components of harm reduction
within needle syringe programme (NSP) environments
[5,6]. Neale’s studies suggest that increased engagement
with OST programmes could be achieved by improving
service delivery, staff communication and attitudes, but
also that IDUs need to be motivated and feel positive
about seeking help for their drug use [7].
This position is set amongst a growing body of litera-
ture which sees OST through a variety of lenses: from a
bio-medical treatment model to socio-cultural control of
deviance model [8,9]. There is also tension between the
harm reduction focus of entering OST and the current
‘Recovery Agenda’ [1]. This underpins national government
drug policy as implemented by Public Health England. It
has been suggested that this agenda could move injecting
drug users into detoxification and abstinence before they
are ready and so perpetuate cycles of problematic drug
use [10].
OST (methadone and buprenorphine) is readily avail-
able via Primary Care in Bristol, UK, with over 90% of
health centres participating in a Shared Care scheme
with staff from Bristol Drugs Project (BDP). Average
waiting times for OST at the time of this trial were
approximately 1 week between GP appointment and
start of prescribing. Despite this relative ease of access,
20-25% of NSP users were not on OST at any one time
(BDP unpublished data 2007–2011), citing difficulties in
getting GP appointments and waiting lists as barriers,
meaning that windows of motivation were missed and
ambivalence returned. Participants in focus groups car-
ried out during 2008/2009 asked for access to same-day
methadone, whereby motivation for treatment could be
harnessed immediately and some of the real or perceived
barriers reduced (BDP unpublished data).
Motivational interviewing (MI) has long been the tool
of choice in substance misuse services; alongside cogni-
tive behavioural therapy, and group or individual skills
training [11]. Systematic reviews of the evidence base for
MI reveal that MI is: particularly effective in enhancing
entry into drug treatment [12]; can reduce the extent of
substance abuse compared to no intervention, [13]); and
that MI and case management approaches to increase
the uptake of injecting drug users into treatment were
both promising but the evidence inconclusive [14].
Markland et al. [15] note that MI is widely used to pro-
mote behaviour change, but lacks a coherent theoretical
framework for understanding its processes and efficacy.They propose that self–determination theory (SDT) can
offer a broad framework for studying and understanding
motivation for change [15].
We have used these models to help understand the out-
comes from a feasibility RCT (‘Script in a Day’ trial) which
offered a ‘same day’ OST (methadone only) prescription
for injecting heroin users compared to usual care. Out-
comes showed little difference between the intervention
and usual care groups in terms of retention on OST at
3 months (Beattie et al. personal communication). ‘Usual
care’ in the city was an appointment with their GP
followed by a wait for urinalysis and a ‘shared-care’ drugs
worker to support prescribing. The trial included this
nested qualitative study in which we sought to explore the
trial processes, understand the effects of and acceptability
of the intervention and outcomes for control participants.
This paper focuses particularly on understanding the posi-
tive outcomes and motivation for change amongst a num-
ber of control group participants, offering motivational
interviewing and self-determination theory [15] as frame-
works for understanding their positive behaviour change
following recruitment to the trial.
Methods
Adult participants were recruited to the trial through the
NSP at Bristol Drugs Project (www.bdp.org.uk) between
October 2011 and September 2012 and if they agreed to
take part, validated questionnaires were completed: the
Treatment Outcomes Profile Measure (TOPS) [16], widely
used in drug services, measuring substance use, injecting
risk behaviour, crime, health & social functioning; the
EQ-5D [17], a health related quality of life and utility sta-
tus measure; and SF-12 a generic health status measure
providing both mental component summary and physical
component summary scores[18]. Participants were then
randomised into the intervention arm (same day appoint-
ment with the intervention GP to obtain a three-week
course of methadone followed by transfer back to their
own GP for on-going care) or control group (advice about
how to contact their own GP to obtain treatment). The
day after recruitment they could return for a payment of
£15 to cover their time involved in the recruitment
process.
At the three month follow-up all participants in the trial
were invited to be interviewed for this qualitative nested
study. A purposive sample was selected from those who
agreed to include both trial arms, males and females, and
a range of ages. The semi-structured interviews were
framed around a topic guide developed from the literature
and discussions between the qualitative team and the
Harm Reduction workers at BDP. Interviews were con-
ducted at BDP and took around 30 minutes each explo-
ring participants’ attitudes to the trial, reasons for joining
the trial and the impact of randomisation to either arm.
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interview.
Interviews were carried out by three Harm Reduction
workers from Bristol Drugs Project, trained to be re-
cruiters and interviewers for the trial. Data collection and
analysis were conducted in parallel and interviews contin-
ued until data saturation was reached with no new themes
arising from the data [19]. This was an iterative process
and towards the end of sampling, greater emphasis was
given to choosing control arm participants, as early inter-
views had revealed a level of motivation to seek and secure
treatment, which seemed to have been generated by
the recruitment appointment itself. Preliminary findings
from early interviews were framed in additional questions
which were then explored in the later interviews with
different participants. Interviews were audio-recorded,
transcribed verbatim, anonymized and coded through re-
peated reading of the transcripts [20]. Four authors (RA,
JI, AR, JN) coded interviews and various combinations of
two authors double coded them all. Thematic analysis
using an inductive approach [21] was used to scrutinise
the data to identify and analyse patterns, themes and sub-
themes across the dataset. Themes and any discrepancies
were discussed extensively with the qualitative researcher
(JI) guiding the process to achieve a coding consensus and
ensure robust analysis.
Ethics approval was given by National Research Ethics
Service, South West (11/H0102/1).
Results
Three hundred and eleven injecting drug users who
attended the needle exchange during the recruitment
period were eligible to join the trial, by reporting that
they were not in receipt of opioid substitution treatment
nor had been during the previous two weeks. One hun-
dred of these consented to take part. At the 3-month
outcome, follow-up data were available for 96 partici-
pants (85 from face-to-face contacts, 11 from medical
records only); 25/48 (52%) in the intervention arm were
on OST and 24/47 (51%) of the control arm. Sixty of
those seen face-to-face agreed to be interviewed for the
qualitative study, and 20 of these were selected for an
interview, eight from the intervention arm and 12 con-
trols; 16 males and four females. This gender mix was
representative of the overall trial composition. Their
mean age was 38 years (range 22 to 53 years) and the
females were slightly younger (mean age 32 years)
compared to the males (mean age 39 years old). Before
taking part in the ‘Script in a Day’ trial, participants had
not been on OST (methadone or buprenorphine) for a
median time of 27 weeks, which perhaps showed some
ambivalence to obtaining OST in trial participants,
given the relative ease of obtaining OST in Bristol at
the time.Themes from the interviews emerged around motiv-
ation to join the trial (starting the journey to recovery
and ambivalence), responses to being randomised from
the intervention (positive) and control (disappointment)
participants, and enhancing motivation for treatment at
recruitment (developing self-efficacy and resolving cog-
nitive dissonance).Motivation to join the trial
Starting the journey to recovery
Reasons cited for joining the trial were primarily a desire
to get on OST. Some were motivated for harm reduction
purposes and others as a step to detoxification and re-
habilitation, which they saw as starting their journey to
recovery:
“I was in a very bad place and was desperate for
something to stabilize me” (#306; Male; 27 y; control).
“I was struggling to inject myself….struggling to find a
vein…in the end it would congeal in the pin and I’d
have to squirt it away … so that’s why when I heard
about (the trial), that’s why it came at the right time”
(#218; Male; 40 y; intervention).
“It was the first step …getting back into recovery…To
get into detox I had to be on 30 mls (Methadone)
maximum. I knew I was on borrowed time. I knew…
that it wouldn’t be long before I was arrested again for
what I was doing to get my drugs” (#127; Male; 50 y;
intervention).
Some participants were already in the process of
securing OST and hoped to speed up the process by
joining the trial:
“I know it can take a long time to get a script through
Shared Care.” “I really do (did) need to go and get a
script anyway, so I did. I went and signed in with the
doctor” (#011; Male; 35 y; control).
“I was desperate at the time, so I had to try all
channels that may have medicated me as quick as
possible…I think I done the test (trial recruitment) on
the Friday and my appointment (for scripting) was
the following Tuesday anyway so…” (#315; Male; 33 y;
control).Ambivalence and previous negative experiences
Most interviewees had either had negative experiences
of getting OST in the past or assumed that it would be
difficult in the future and this had become a barrier to
seeking treatment from their GP in primary care or any
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was therefore an attractive option:
“I’d been thinking about getting scripts myself, but the
process seemed long and daunting…that ‘in-a-day’
thing caught my attention, I thought “yeah”
(#106; Female; 33 y; intervention).
“Even if you know where to go (i.e. to the GP) there’s
this thing of like, you know, er “phew they ain’t gonna
be interested in sorting me out, d’you know?”
(#310; Male; 40 y; control).
Despite relatively short waiting times for OST in Bristol,
any wait can feel too long and may result in a loss of mo-
tivation and missed appointments. Participants talked
about length of time to book a GP appointment, needing
to provide a urine sample and returning for a second ap-
pointment and prescribing. For some, prescribing could
not start until a shared care worker was also available.
“Several times I have made doctor’s appointments but
when the day has come I’ve been alright that day so
I’ve not bothered” (#218; Male; 40 y; intervention).
“It takes forever to get a script, so (when) you said
‘script-in-a-day’, obviously I took an interest…”
(#009; Male; 46 y; intervention).
“The last time I got a script through my doctor it
took ages, …I think it took about three weeks, so it
was like a joke” (#108; Male; 30 y; intervention).
A minority of health centres in Bristol do have long
waiting lists and one or two still do not provide OST for
opiate users:
“I’d had problems trying to get scripted at XX health
centre, even though I lived in the area there was a
long waiting list” (#306; Male; 27 y; control).
“The trial for me was beneficial. Because my – my
doctor’s surgery, like my normal GP, doesn’t prescribe
methadone” (#127; Male; 50 y; intervention).
Intervention participants’ responses to randomisation
A very positive response was expressed by all eight inter-
viewees who were randomised into the intervention arm.
“For it to actually happen (get a same day script) was
brilliant” (#218; Male; 40 y).
“Fantastic. So quickly, it was fantastic, instead of
having to wait …” (#101; Female; 36 y).Positive impacts of securing same-day methadone
The same-day prescription resulted in immediate self-
reported improvements in several domains.
Crime reduction: removing the need to commit crime
to fund a habit gave time to concentrate on improving
health and relationships.
“It turned my life around and in a short space of time
I didn’t have to go out and commit crime to fund, to
get drugs (#108; Male; 30 y).
“I could go to sleep thinking “it doesn’t make any
difference at all if I wake up with no money at all” I
know that in the morning when I wake up all I’ve got
to do is walk round to the chemist and I’m ok for the
day and I don’t have to risk my liberty…to fund”
(#218; Male; 40 y).
Health improvements, reduction in stress and in drug
use:
“I’m not injecting myself left right and centre …
you don’t see me down here (at the NSP) anymore
very often … its just a hell of a lot better …
100% better. I’m eating better, everything”
(#009; Male; 46 y).
“I haven’t gotta worry about waking up in the
morning feeling ill, not wanting to come out,
feeling lethargic, feeling irritable. Relationship-wise
is just absolutely brilliant, absolutely great”
(#219; Female; 28y).
“Through getting the script … it was the biggest
stress that I had going on in my life, taken care of”
(#109; Male; 41 y).
“It takes the amount you’re using down … I don’t
have to use it (heroin) every day…from using a
gram a day to sometimes maybe a bag a day”
(#106; Female; 33 y).
A step to independence, increased sociability and
self-care:
“I think it’s fantastic. Without it I wouldn’t be
clean today and doing what I’m doing and getting
on with my life (#101; Female; 36 y).
“It was my first step into … getting back into
recovery…that’s the sort of way in for a lot of
people, then other work can start, the work to start
changing behaviours and lifestyles and things like
that” (#109; Male; 41 y).
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scription was reported as both a positive and straight
forward process:
“It was tremendous I was blown over…I timed from
when I first… took part in the trial…contacting the
surgery, arranging an appointment, seeing the doctor,
being prescribed, the whole thing was just under…two
hours (#109; Male; 41 y).
“Within half an hour I got it, picked up my
methadone from the chemist and then I was on daily
pick up” (#218; Male; 40 y).
However, one participant reported the negative impact
she felt after her need to use heroin had been addressed
via methadone, where loss of routine and regular contact
with using associates left a void
“Normally I start my day at 11 o’clock, make money
and have a hit. Then I got out of bed and I’d think
“what do I do?” I didn’t see the friend I normally see
to associate with. I suddenly felt all in a big space not
knowing what to do with it really, so it was a bit
daunting”…it was a big thing feeling “what do I do
now” (#106; Female; 33 y).
Control participants’ responses to randomisation
Disappointment and negative thoughts
The response to being randomised to the control arm
was universally disappointing. Whether or not the indi-
vidual was ambivalent at the point of recruitment, desire
for treatment grew during the recruitment appointment
when health questionnaires and drug audits were com-
pleted and responses were strongly expressed:
“It was pretty heart breaking when I got the control
group” (#306; Male; 27 y).
“Yeah I was devastated” “I knew that I had to go back
out and buy street drugs, and I did not want to, I
really didn’t. I’m sick and tired doing street drugs”
(#219; Female; 28 y).
“Gutted” “yeah really, really disappointed, yeah.”
“…Yeah sort of when you take a stab at something
and you get knocked back it sort of makes you think,
Phew, why did I bother in the first place?”
(#122; Female; 29 y).
“…they said “now you’ve got to get a GP, you’ve
got to get a drugs worker” and all, so it all seems
like a big hill, d’you know?… when you’re out there
as an addict on the street, it’s er getting it together
to do these normal things, I know it doesn’t sounda lot, but it’s er hard work staying on top of
things” (#310; Male; 40 y).
“I knew I wouldn’t be able to get a script quickly
elsewhere…” (#011; Male; 35 y).
Only two interviewees from the control group were
phlegmatic about their outcome:
“I know (knew) I need to (register with a GP) but
its finding one that will take you on when you
are NFA (no fixed abode) and all the rest of it”
(#310; Male; 40 y).
“I thought to myself - at the end of the day, at
least someone had taken the time and effort to try
and help me on the road to getting a script”
(#006; Male; 22 y).
Enhancing motivation for treatment at recruitment
The role of recruitment
Early qualitative interviews indicated that participants
may have experienced a shift from ambivalence towards
motivation for treatment during the trial recruitment ap-
pointment itself and in particular through completing
the self-evaluation questionnaires. This may partly ex-
plain the extreme disappointment expressed by most of
those recruited to the control arm.
“It made me think a lot actually about myself…I don’t
actually sit down and think about my overall day,
usage or anything like that. But when I was going
through the questionnaire I actually did think about
“God … things aren’t quite as good as I thought they
were” (#219; Female; 28 y; control).
“It felt a bit personal, answering some of the
questions, .. I thought, it’s all for a good cause, it’s
helping me in the long run, these are some things I
haven’t even asked myself about myself… I went
home, it gave me a bit of time to reflect on my er own
personal experience a bit more deeply that I usually
would” (#006; Male; 22 y; control).
Developing self-efficacy
Drug users can experience a great deal of pressure to be
in treatment (including from family and friends, the
criminal justice system, primary health and specialist
services) which can provoke resistance or undermine
self- efficacy:
“..previously I’ve had scripts almost forced on me…
through like er drug treatment testing orders or drug
rehabilitation requirements, whatever, and I carried
on using street drugs,” (#310; Male; 40 y).
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seemed to offer a sense of autonomy:
“..came in just because the trial was going on to be
honest with you…it gave me the er – the push that I
think I needed…..it put something in my head… well
alright, you know, it didn’t happen (getting the
same-day script), ..but it’s not the end of the world.
You know, you can make it happen if you chose, and
that’s what I did you know” (#007; Male; 53 y).
“I went home it gave me a bit of time to reflect on my
er own personal experiences a bit more deeply than I
usually would.” “It’s helped motivate me into realising
that I can do it myself and I don’t need outside
support all the time.” (#006; Male; 22 y).
Resolving dissonance
Having experienced an increase in motivation and then
subsequent disappointment at being randomised to the
control arm, 24/47 participants (51%) went on to secure
OST (methadone or buprenorphine) within the three
month trial period and six of these were interviewed:
“.. once they said I was in the control group then I
thought, you know, “I really do need to go and get a
script anyway”, so I did, I went and signed in with the
doctor…” (#011; Male; 35 y).
“I suppose it made me get off me bum and go and get
a script somewhere else” (#002; Male; 43 y).
Changing/adding cognitions
Those recruited to the control arm who didn’t secure
OST within the three month follow-up period cited vari-
ous barriers. Two recruits talked about long waiting
times and changes in motivation; neither had actually
tried to make appointments.
“…with the doctors I’m with, you’ve gotta wait weeks
for an appointment with a normal doctor, and then
weeks again for an appointment with a doctor that
can help you with a medicated script. So you’re
looking at a month, maybe even more. And, you
know, if you’re using that whole entire month, the
likelihood is you ain’t gonna make those
appointments, and that’s been the case with me really”
(#122; Female; 29 y).
“It’s quite hard to get an appointment ‘cos you’ve
gotta ring first thing in the morning, and if you
haven’t got credit and that, you can’t get one basically,
and there’s only certain doctors that deal with scripts
and er – in this area – and there’s a lot of people thatare on drugs, and they take up all the appointments
straight away” (#114; Male; 35 y).
Another had made two GP appointments but missed
them:
“I tried to get a script through him (GP) but I was
missing appointments and things like that, so I never
got the script” (#015; Male; 48 y).
One participant talked about a previous positive ex-
perience with buprenorphine and cited a reluctance to
start back on methadone as a barrier, despite being dis-
appointed at being randomised to the control arm:
“I wanted to be back on the subu (buprenorphine), so
it was taking a step back, I thought by going back
onto Methadone” (#143; Male; 44 y).
Discussion
The feasibility trial found that there were no differences
between the intervention and control groups in terms of
numbers who were still on OST (methadone or bupre-
norphine) at three months. This nested qualitative study
has shown how taking part in the trial enabled several in
the intervention arm to secure OST, detoxify and achieve
freedom from their problematic drug use. For others,
remaining on OST reduced their injecting drug use and
allowed for the building of ‘recovery capital’ [1]. A small
number of intervention arm recruits were no longer on
OST at three months. One intervention group interviewee
illuminated the risk of providing a pharmacological inter-
vention (methadone) in the absence of psycho-social sup-
port, where the sudden absence of a drug-using routine
and associated friendships, left a destabilising void. This
perhaps adds to the current dialogue about potential risks
associated with early entry into ‘Recovery’ [10], driven by
the Recovery Agenda [1].
All recruits to the trial said they were ‘interested’ in
securing OST but, despite the relative ease of access to
OST in Bristol, had faced barriers (real or perceived)
and had not been able or motivated to do so in the
period prior to recruitment. For those in the control
arm, completing the baseline questionnaires appeared to
create some cognitive dissonance between their current
health state and their personal aspirations, which was
not immediately resolved by being offered treatment
within the trial.
All control arm participants expressed disappointment
at not being in the intervention arm. However, over 50%
went on to secure OST. We offer the following expla-
nation of why this group of individuals may have chosen
to seek treatment independently. Cognitive dissonance
theory is founded on the assumption that individuals
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reality and will strive to reduce the discomfort that any
discrepancy between the two causes [22]. Exploring this
in terms of self-determination theory may begin to ex-
plain why many of those in the control arm had better
outcomes than expected.
Motivation for change builds when individuals start to
perceive discrepancy between current and desired beha-
viour (ambivalence) and then options to resolve the cog-
nitive dissonance experience are identified [23]. This is
usually the first, (directive) step in Motivational Intervie-
wing (MI) for eliciting behaviour change, a technique with
an established evidence base in the substance misuse field
[24,13]. In the context of recruitment to this trial, there
was no premeditated, attempt by the interviewers to de-
velop a discrepancy with the intention of eliciting behav-
iour change. However, we postulate that carrying out a
self-evaluation of health and social wellbeing through the
baseline questionnaires at the recruitment appointment,
provoked cognitive dissonance [22] between the partici-
pants’ status quo and their core values or aspirations; one
of the first stages in an MI intervention.
Festinger [22] described the necessity to resolve ‘disson-
ance related discomfort’ quickly. Whilst the autonomic
discomfort of enhanced dissonance is thought to be very
short-lived (minutes) its effects may last up to two weeks
[25]. It may be that some of those recruited to the control
arm of the trial, resolved their dissonance by seeking and
securing treatment within a short period following re-
cruitment to the trial (mostly within 2 weeks). In others,
dissonance may have been reduced by changing their cog-
nitions to fit their behaviour and justifying on-going drug
use, due to external pressures (such as difficulties in get-
ting GP appointments) or by shifting emphasis or respon-
sibility, perhaps by minimising the impact of their drug
use or wanting something that was not available via the
trial, such as a prescription for buprenorphine instead of
methadone. Self-Determination Theory (SDT) [26] may
further illuminate the drive to seek treatment that was
seen after recruitment to the control arm. SDT suggests
that individuals have innate tendencies towards personal
growth and wellbeing and Cognitive Evaluation Theory (a
sub-theory within SDT) specifies three fundamental psy-
chological needs that must be facilitated for this to happen.
These are: competence (facilitated when individuals are
helped to develop clear expectations about what behaviour
change could do for them), autonomy (pressure to engage
in specific behaviours is minimised and individuals are
encouraged to take action themselves, recognising that they
have a choice regarding their behaviour) and connectedness
(from supportive families or social networks, but may also
be facilitated by supportive and respectful professional rela-
tionships) [27]. This model of understanding motivation for
change through SDT is explored by Markland et al. [15].We suggest that by choosing to participate in this trial,
completing a self- evaluation of drug and alcohol use and
quality of life questionnaires, conditions that supported
change were created. Firstly, cognitive dissonance occurred
as the participant described a picture of themselves at re-
cruitment. A sense of competency, as described above,
may have grown as the trial recruitment questionnaires
illuminated broad areas of physical, emotional and social
wellbeing that might benefit from behaviour change
through access to OST. The route into treatment for drug
dependency is well known in Bristol and as participants
randomised to the control arm were given information
about how to get OST via their GP (usual treatment) it
may be that, for some of them, a sense of autonomy was
fostered alongside a heightened desire for change. Many
recruits may have had experience of mandated or coerced
treatment via the criminal justice system, or pressure for
treatment from concerned others (families and friends) or
treatment agencies. For the recruitment appointment, the
researchers were trained to adopt an impartial position and
this attitude to treatment from research staff may have re-
duced external pressure and increased a sense of autonomy
and internal motivation. The connectedness component is
less clear, but we could speculate that time spent with re-
searchers in a supportive but impartial environment added
in a small way to this sense of feeling ‘related’ or ‘connected
positively’ with others. In SDT terms, autonomy is seen as
a continuum “reflecting the extent to which the person
fully endorses and is committed to what they are doing”
[15]. This moment of recruitment to the control arm may
have pushed some individuals further along the continuum
from external to a more self-determined form of regula-
tion. Thus the valued outcome of behaviour change may
have been indirectly highlighted during recruitment, along-
side an enhanced sense of self-efficacy, resulting in an in-
creased determination to seek OST.
Strengths and limitations
The number of interviews in this study was relatively
small but saturation was reached and no new themes were
emerging from the data by the end of the interviews. The
strengths of this study included the use of Harm Reduc-
tion workers, who were known to the participants, to con-
duct the interviews and this increased the participants’
confidence and enabled them to talk freely. The workers
were also an intricate part of the analysis which helped the
researchers to gain insights into the meanings of the in-
terviews. However the use of ‘known’ researchers for the
interviews may also have influenced what participants
disclosed about the impact of their drug use, either exag-
gerating or minimising the impact, if it was felt that this
might influence the researchers’ view of them. The quali-
tative interviews did not seek to gain insight into how dis-
sonance was resolved. Our focus in this paper has been to
Ayres et al. Substance Abuse Treatment, Prevention, and Policy 2014, 9:44 Page 8 of 9
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arm participants went on to secure OST. We recognise
that we have not attempted to explain why others in the
control arm chose not to pursue treatment.
Implications for practice
Incentivising service users to participate in Harm Reduction
programmes is well established. Accepting that current UK
drug treatment policy is to encourage injecting heroin users
into OST as quickly as possible, this study illuminates a
useful intervention that could be rolled out in NSP en-
vironments. We suggest that a regular ‘health evaluation’
for injecting drug users is carried out, similar to the alcohol
brief intervention tool, AUDIT [28,29], a self-completion
questionnaire which can develop a discrepancy between
drinking behaviour and view of self, raise anxiety and result
in changes in alcohol use [30]. This ‘health evaluation’ tool
could be offered to injecting drug users who are not cur-
rently in treatment with incentives for participation. Such
a mechanism for encouraging OST uptake should be
delivered without pressure for change and paired with
increased access to low-threshold and evidence-based
treatment.
Conclusions
Taking part in the trial enabled participants in the ‘script
in a day’ intervention arm to gain same-day access to OST
and reduction in their drug use. For those in the control
arm, completing the baseline questionnaires appeared to
create cognitive dissonance between their current health
state and own aspirations, so increasing motivation for
and access to treatment. Many obtained and were still in
receipt of OST at the 3 month follow-up.
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